Autologous saphenous vein remains the conduit of choice for infrainguinal bypass grafting and continues to have widespread use for coronary bypass grafting as well, despite its disappointing long-term patency rate. [1] [2] [3] Vein grafts undergo morphologic and functional changes after insertion into the arterial circulation, with significant alterations in endothelial and smooth muscle cell activity leading to the development of intimal hyperplasia. 4, 5 Because it is at the interface between the blood and the vessel wall, normally functioning venous endothelium is essential for vascular homeostasis. It produces prostacyclin and nitric oxide (NO), both of which are potent vasodilators as well as inhibitors of platelet aggregation. Several studies have shown that the dysfunctional endothelium of arterial vein grafts manifests decreased ability to vasodilate in response to endothelium-derived relaxing factor or NO, reduced prostacyclin production, and decreased fibrinolytic activity. [6] [7] [8] [9] The endothelium is also involved in modification to the structure of the vessel wall through the secretion of factors that affect underlying cellular growth and regression. [10] [11] [12] [13] [14] Vascular endothelial growth factor (VEGF) is a potent angiogenic growth factor that is endothelial cell-specific and does not stimulate the proliferation Reduction of vein graft intimal hyperplasia and preservation of endotheliumdependent relaxation by topical vascular endothelial growth factor Zhengyu Luo, MD, Takayuki Asahara, MD, Yukio Tsurumi, MD, Jeffrey M. Isner, MD, and James F. Symes, MD, Boston, Mass.
Purpose: Recent evidence suggests that vascular endothelial growth factor (VEGF), in addition to stimulating angiogenesis, also serves a repair/maintenance or survival function, modulating various aspects of endothelial cell function. This study was designed to examine the effect of VEGF pretreatment in a model of vein graft intimal hyperplasia. Methods: Reversed jugular vein-to-common carotid artery interposition grafts were constructed in New Zealand White rabbits. Vein conduits were immersed in solution containing 500 mg rhVEGF 165 or saline solution for 20 minutes before implantation. Twenty-eight days later the vein grafts and contralateral control jugular veins were harvested for either histologic or isometric tension studies. Results: VEGF-treated vein grafts showed a 23% reduction in intimal area (0.76 ± 0.07 mm 2 vs 0.98 ± 0.06 mm 2 ; p = 0.028) and a 30% reduction in intimal thickness (62 ± 6 mm vs 89 ± 5 mm; p = 0.001) when compared with control grafts. After precontraction with norepinephrine, the maximal relaxation to acetylcholine (endothelium-dependent, receptor-mediated agonist) for control vein grafts was 0%, whereas for VEGF-treated vein grafts it was 25% ± 9% (p < 0.05 vs control grafts). The maximal relaxation to the calcium ionophore A23187 (endothelium-dependent, receptor-independent agonist) was also greater in VEGF-treated grafts than in control grafts (172.3% ± 19.4% vs 122.5% ± 13.7%; p < 0.05). There was no difference in the response to sodium nitroprusside (endothelium-independent agonist) between the two groups. of other cell types, such as fibroblasts or vascular smooth muscle cells. 15, 16 Recent evidence suggests that VEGF, in addition to stimulating angiogenesis, also serves a repair/maintenance or survival function, modulating various aspects of endothelial cell function. Ku et al. 17 reported that VEGF induces endothelium-dependent relaxation in canine coronary arteries by stimulating endothelium-derived relaxing factor/NO via a calcium-dependent mechanism. A previous study from our laboratory showed that topical application of VEGF to balloon-injured rat carotid arteries significantly accelerates reendothelialization, thus abrogating the cascade of events that leads to neointima formation and restenosis. 18 In addition, we demonstrated that VEGF induces recovery of disturbed endotheliumdependent flow in the rabbit ischemic hindlimb 19 and that VEGF stimulates production of NO when applied to quiescent, endothelium-intact vascular segments from the thoracic aorta, pulmonary artery, and inferior vena cava of New Zealand White rabbits. 20 This response can be blocked by competitive inhibition of nitric oxide synthase (NOS), suggesting that the putative maintenance functions of VEGF may include regulation of baseline synthesis, release of endothelial cell NO, or both.
With this background, the present study was designed to determine whether treatment of venous conduits with VEGF before their implantation in the arterial system would result in better preservation of endothelial function, a reduction in intimal hyperplasia, or both. All rabbits were anesthetized with intramuscular ketamine (50 mg/kg) and xylazine (5 mg/kg). Operations were performed with an operating microscope (STEMI SR, Zeiss, Germany) under sterile conditions. After exposure through a midline neck incision, a 2.5 cm segment of right external jugular vein was carefully dissected and excised. The venous conduit was flushed gently with heparinized saline solution and then immersed for 20 minutes in a 1 ml saline solution (0.9% saline with 0.1% albumin, heparin 5 IU) containing either 500 mg VEGF (test group) or saline solution only (control group).
MATERIAL AND METHODS

Forty
This dosage was arbitrarily selected in part on the basis of previous demonstrations that 500 mg administered as an intraarterial bolus induced angiogenesis in a rabbit model of hindlimb ischemia 19 and 100 mg administered topically promoted reendothelialization in the balloon-injured rat carotid artery. 18 After intravenous administration of 200 IU/kg heparin, the ipsilateral common carotid artery was dissected. The reversed venous conduit was anastomosed proximally and distally to the artery in an end-to-side manner with interrupted 8-0 polypropylene suture. The common carotid artery was then ligated and divided between the two anastomoses with 5-0 suture, and the wound was closed in layers.
Pathologic assessment. At 4 weeks after operation, eight rabbits from each group were anesthetized as above and perfusion-fixed in situ at 100 mm Hg with an initial infusion of heparinized saline solution (1000 IU/L) followed by 100% methanol. Tissues were embedded in paraffin and then processed for light microscopy. Each graft was divided into a proximal, middle, and distal third. Evans blue staining evaluation. At 3 days and at 4 weeks after surgery, two rabbits from each group received an intravenous injection via the ear vein of 4 ml 0.5% Evans blue dye 30 minutes before they were killed to allow macroscopic identification of any areas of endothelial denudation.
Scanning electron microscopy. To further evaluate the endothelial morphologic features, both control and VEGF-treated vein grafts harvested 12 hours and 4 weeks after surgery, along with normal jugular veins (two rabbits each group), were studied using scanning electron microscopy. Harvested vessels were fixed overnight at 4°C in 2.5% glutaraldehyde in 0.13 mol/L cacodylate buffer, pH 7.4. After being rinsed in buffer, specimens were postfixed in 1% ostium tetroxide at 4°C for 1.5 hours, rinsed in cacodylate buffer, and dehydrated through graded concentrations of ethanol. The specimens were critical point-dried from 100% ethanol with liquid CO 2 . The specimens were then bisected to expose the luminal surface, mounted on stubs, and sputter-coated with gold. The samples were viewed and photographed at 10 kV with a scanning electron microscope (model ISI-DS 130, International Scientific Instrument, Paramus, N.J.). Photomicrographs were taken at 1.66 K magnifications.
Physiologic assessment. Four weeks after operation, the contralateral jugular veins and vein grafts from six rabbits in each group were isolated, and a 5 mm ring was excised in situ from the middle segment of each graft as well as from the normal jugular vein. Each ring was immediately mounted between two stainless steel hooks in an organ chamber containing 10 ml Krebs-Henseleit solution (NaCl, 118 mmol/L; KCl, 4.7 mmol/L; MgSO 4 , 1.2 mmol/L; CaCl 2 , 2.5 mmol/L; NaHCO 3 , 25 mmol/L; KH 2 PO 4 , 1.2 mmol/L; glucose, 11 mmol/L) at 37°C and were gassed with 95% O 2 /5% CO 2 . One hook was fixed to the bottom of the bath, and the other was connected to an FT-03 force transducer (Grass Instrument Co. Quincy, Mass.) for recording of changes in force on a Grass 7D polygraph recorder. The vessels were placed under 0.5 g tension and were allowed to equilibrate in Krebs-Henseleit solution for 1 hour. After equilibration, the rings were progressively stretched to optimal tension to establish a length/tension relationship by stretching and stimulation with 60 mmol/L KCl. The cumulative dose-response curve to norepinephrine (10 -9 to 10 -4 mol/L) was determined. After maximal precontraction with norepinephrine, relaxation in response to acetylcholine (10 -8 to 10 -4 mol/L), calcium ionophore A23187 (10 -8 to 10 4 mol/L), and sodium nitroprusside (10 -8 to 10 -4 mol/L) was measured. The vessels were allowed to reequilibrate for 30 minutes between each experimental run. All drugs were prepared daily in distilled water except calcium ionophore A23187, which was dissolved in dimethyl sulfoxide.
The isometric responses of the vessel rings were converted to a percent of maximal response, and these values were then plotted against the negative logarithm of the agonist concentration to produce dose-response curves. The maximal contractile response of each ring to each agonist was expressed in grams of force developed. Relaxation in response to an agonist was expressed as the percentage decrease from the maximal contractile tension developed to norepinephrine.
Reagents. The 165-amino acid heterodimeric species of recombinant human VEGF (rhVEGF 165 ) purified from transfected Chinese hamster ovary cells as previously described 21 was the generous gift of Genentech Inc., South San Francisco, Calif. The purity of the material was assessed with a silverstained SDS PAGE gel and by the presence of a single NH 2 -terminal amino acid sequence. Other reagents were purchased from Sigma Chemical Co.
(St. Louis). Fresh stock solutions were prepared immediately before each experiment.
Data and statistical analysis. All data were evaluated with two-tailed, unpaired Student's t test or compared by one-way analysis of variance followed by Fisher's t test and expressed as the mean ± SEM. A p value less than 0.05 was considered statistically significant.
RESULTS
All grafts were patent at harvest. The endothelium of both control and VEGF-treated vein grafts harvested at 3 days and at 4 weeks after surgery appeared grossly intact, demonstrating no obvious Evans blue staining. Scanning electron microscopy showed a continuous layer of endothelium on the surface of normal jugular vein. Endothelial morphologic features appeared to be minimally altered in all grafts. Both control and VEGF-treated vein grafts harvested 12 hours after implantation demonstrated only localized areas of endothelial separation or loss. These areas were covered with red blood cells and platelets (Fig. 1, A and B) . Four weeks after surgery, scanning electron microscopy showed that both control and VEGF-treated vein grafts were covered by a continuous layer of endothelial cells, with minimal differences between groups (Fig. 1, C and D) .
Intimal hyperplasia. Sample sections of a normal vein, a control vein graft, and a VEGF-treated vein graft are shown in Fig. 2 . The extent of intimal thickening is seen to be significantly reduced in the VEGF-treated graft. Because the internal elastic lamina of transplanted jugular vein is often somewhat ill-defined by light microscopy, we did not attempt to calculate the intimal/media ratio in this study (Fig. 2) .
Dimensional analysis of vein grafts from the proximal, middle and distal segments was performed. Because only slight differences were observed between segments, the results were averaged and are shown in Table I . VEGF-treated vein grafts manifested a 23% reduction in intimal area (0.76 ± 0.07 mm 2 vs 0.98 ± 0.06 mm 2 ; p = 0.028), a 30% reduction in intimal thickness (62 ± 6 mm vs 89 ± 5 mm; p = 0.001), and a 13% increase in intimal circumference (12.44 ± 0.50 mm vs 11.03 ± 0.34 mm; p = 0.013) when compared with control grafts.
Endothelial function studies. There were no significant differences between the normal jugular veins from the control and VEGF-treated groups in the relaxation response to acetylcholine, calcium ionophore A23187, and sodium nitroprusside, or in the contractile response to norepinephrine. Normal jugular veins and VEGF-treated vein grafts both relaxed to acetylcholine (receptor-mediated, endothelium-dependent relaxation), whereas control vein grafts did not. Relaxation to acetylcholine, expressed as percent change from the baseline after maximal precontraction (100%), was 0 for control grafts, 25% ± 9% for VEGF-treated grafts (p < 0.05 vs control grafts) and 59.5% ± 8% for normal veins (Fig. 3, A) . There was also a significant difference in the maximal relaxation to calcium ionophore A23187 (receptor-independent, endothelium independent relaxation) in VEGF-treated vein grafts compared with control grafts (172.3% ± 19.4% vs 122.5% ± 13.7%; p < 0.05) and jugular veins (125.2% ± 7.8%; p < 0.05 vs VEGF-treated grafts; Fig. 3, B) . There was no significant difference in the response to sodium nitroprusside (endotheliumindependent relaxation) in either control or VEGFtreated vein grafts (control, 163.5% ± 19.4%; VEGF, 169.0% ± 19.1%; p > 0.05; Fig. 3, C) . Both vein grafts demonstrated significantly greater maximal relaxation than did normal veins to this agonist.
DISCUSSION
VEGF, also known as vascular permeability factor, has been shown to be an endothelial cell-specific mitogen in vitro and an angiogenic growth factor in vivo. 15, 22, 23 Recent studies have demonstrated that VEGF and its specific receptors, namely flk-1 (KDR) and flt-1, are abundantly expressed in embryonic vasculature and hypoxic adult tissues. 24, 25 The widespread expression and organ-specific distribution of VEGF mRNA and protein in normal rat tissues support the concept that VEGF may play a multifunctional role in the maintenance of vascular function other than mediating vascular growth. 26, 27 We previously demonstrated that direct application of VEGF recombinant protein to the denuded surface of the rat carotid artery accelerates reendothelialization and leads to reduced neointimal proliferation. 18 More recently we showed that VEGF stimulates production of NO when applied to endothelium-intact vascular segments from the thoracic aorta, pulmonary artery, and inferior vena cava of New Zealand White rabbits, inferring the presence of functional receptors on the quiescent endothelium of the adult rabbit. 20 That this response is blocked by competitive inhibition of NOS suggests that the putative maintenance functions of VEGF may include regulation of baseline synthesis, release of endothelial cell NO, or both, supporting the notion of a "survival" or "maintenance/repair" role for VEGF. Furthermore, the demonstration that VEGF is capable of inducing recovery of disturbed endothelium-dependent flow in the rabbit ischemic hindlimb may reflect restored NO production by endothelial cells that are initially damaged by protracted ischemia in the collateraldependent limb. 19 Some degree of intimal thickening in vein grafts has been viewed as an adaptation to the switch from venous to arterial hemodynamics. 28, 29 Increased tangential stress (applied transversely to the vessel wall) stimulates intimal thickening, whereas increased shear stress (applied longitudinally) leads to regression. 30 Noris et al. 13 have suggested that this effect is modulated by transcriptional activation of NO synthase as a result of the shear stress effect on endothelial cells. The increased release of NO could in turn induce intimal regression by several mechanisms, including inhibition of smooth muscle cell proliferation or even cell death, reduced expression of adhesion molecules that prevents recruitment of inflammatory cells (a source of growth factors), or decreased collagen synthesis by smooth muscle cells. 30 Thus the essential role played by the endothelium (in particular, its ability to release NO) in the development of intimal hyperplasia and subsequent vein graft occlusion is becoming increasingly recognized. Loss of NO-mediated relaxation is characteristic of intimal hyperplastic lesions. 10, 31 In addition to its role as a vasodilator, studies 32, 33 have shown that NO inhibits platelet adhesion and aggregation, reduces neutrophil interaction with the endothelial surface, and may neutralize superoxide radicals. Furthermore, increased NO synthesis by the endothelium may directly inhibit underlying smooth muscle cell proliferation. 31, 33 As a result, a number of studies have attempted to inhibit intimal thickening that is responsible for compromised arterial patency by increasing the availability of NO. Davies et al. 34 showed that oral administration of the NO precursor L-arginine 7 days before operation and thereafter until harvest 28 days later significantly reduced intimal hyperplasia and preserved endothelium-derived relaxation in the rabbit vein graft model. McNamara et al. 35 demonstrated that L-arginine inhibited intimal hyperplasia after balloon angioplasty and that this effect was completely blocked by the NO synthase (NOS) inhibitor L-NAME. Recently, we showed that VEGF stimulates NO release from quiescent rabbit and human vascular endothelium, and this response can also be blocked by competitive inhibition of NOS. 20 These in vivo studies, in combination with the in vitro findings, suggest that NO is at least in part responsible for mediating the effect of VEGF on endothelial function and intimal hyperplasia in this experiment.
In the present study, we demonstrate that a single topical application of VEGF before implantation preserves endothelium-dependent relaxation and reduces intimal hyperplasia in a rabbit vein graft model. In control vein grafts, receptor-mediated, endotheliumdependent relaxation was lost and did not respond to acetylcholine. In contrast, VEGF-treated grafts relaxed in a dose-dependent manner to acetylcholine as well as manifesting greater maximal relaxation to the receptor-independent, endothelium-dependent agonist calcium ionophore A23187 compared with control grafts. The superior relaxation response of both control and VEGF-treated grafts to sodium nitroprusside compared with normal veins may be explained by a specific "supersensitivity" to nitrovasodilators in the setting of absent or impaired baseline NO-mediated tone, as proposed by Moncada et al. 36 Previous work has described endothelial surface changes including altered morphologic characteristics and denudation in a variety of circumstances in autologous vein grafts. In this study, however, the endothelium of the vein grafts appears relatively intact as seen in vein grafts treated with Evans blue and by scanning electron microscopy. Therefore, the reduction in intimal hyperplasia seen here may not be via the mechanism of reendothelialization, as was evident in our previous rat carotid artery balloon injury model. 18 Instead, the endothelium of these vein grafts likely undergoes "type I" injury in which the endothelium is rendered dysfunctional while remaining more or less morphologically intact. 37 Thus the endothelium of vein grafts in the arterial circulation, although morphologically similar to normal venous endothelium, appears to be functionally impaired with regard to its vasomotor reactivity.
Although current surgical techniques of vein grafting aim to minimize endothelial damage, an unstable state is created in which both endothelial and smooth muscle cell function are altered. The processes that lead to intimal hyperplasia and the changes in endothelial and smooth muscle cell phenotypes begin early after grafting into the arterial circulation. Therefore, interventions that are designed to control these lesions should be initiated before or at the time of vein grafting. In this respect, the intraoperative approach described here, which involves only a short period of topical application with no preimplant or postimplant administration, may have considerable practical merit.
CONCLUSION
We demonstrated that simple immersion of vein grafts in a solution containing the endothelial cell-specific mitogen VEGF before implantation reduces intimal hyperplasia and preserves endothelial function in a rabbit vein graft model. Although the exact mechanisms by which VEGF exerts its beneficial effect cannot be fully addressed by this in vivo study, its known effect on NO production appears to be important. Further evaluation of this novel approach to improving vein graft patency appears warranted. 
